company background image
660

Wai Chun Bio-TechnologySEHK:660 Stock Report

Last Price

HK$0.054

Market Cap

HK$90.8m

7D

3.8%

1Y

-16.9%

Updated

19 Jan, 2022

Data

Company Financials
660 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

660 Stock Overview

Wai Chun Bio-Technology Limited, an investment holding company, manufactures and sells modified starch and other biochemical products in the People’s Republic of China.

Price History & Performance

Summary of all time highs, changes and price drops for Wai Chun Bio-Technology
Historical stock prices
Current Share PriceHK$0.054
52 Week HighHK$0.17
52 Week LowHK$0.045
Beta0.19
1 Month Change-1.82%
3 Month Change0%
1 Year Change-16.92%
3 Year Change-86.15%
5 Year Change-94.13%
Change since IPO-78.40%

Recent News & Updates

Shareholder Returns

660HK FoodHK Market
7D3.8%-3.2%0.3%
1Y-16.9%-24.2%-16.0%

Return vs Industry: 660 exceeded the Hong Kong Food industry which returned -24.2% over the past year.

Return vs Market: 660 matched the Hong Kong Market which returned -16% over the past year.

Price Volatility

Is 660's price volatile compared to industry and market?
660 volatility
660 Average Weekly Movement9.0%
Food Industry Average Movement5.5%
Market Average Movement6.7%
10% most volatile stocks in HK Market13.2%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 660 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 660's weekly volatility has decreased from 14% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a127Ching Kui Lamhttps://www.0660.hk

Wai Chun Bio-Technology Limited, an investment holding company, manufactures and sells modified starch and other biochemical products in the People’s Republic of China. It also trades in electronic parts and components, and electrical appliances; and athletic and athletic-style footwear, as well as working, safety, golf, and other functional shoes. The company was formerly known as Wai Chun Mining Industry Group Company Limited and changed its name to Wai Chun Bio-Technology Limited in September 2019.

Wai Chun Bio-Technology Fundamentals Summary

How do Wai Chun Bio-Technology's earnings and revenue compare to its market cap?
660 fundamental statistics
Market CapHK$90.76m
Earnings (TTM)-HK$12.70m
Revenue (TTM)HK$608.32m

0.1x

P/S Ratio

-7.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
660 income statement (TTM)
RevenueHK$608.32m
Cost of RevenueHK$555.81m
Gross ProfitHK$52.51m
ExpensesHK$65.21m
Earnings-HK$12.70m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0076
Gross Margin8.63%
Net Profit Margin-2.09%
Debt/Equity Ratio-1,325.7%

How did 660 perform over the long term?

See historical performance and comparison

Valuation

Is Wai Chun Bio-Technology undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Wai Chun Bio-Technology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Wai Chun Bio-Technology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Wai Chun Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.3%

Forecasted Food, Beverage & Tobacco industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Chun Bio-Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Wai Chun Bio-Technology performed over the past 5 years?

24.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 660 is currently unprofitable.

Growing Profit Margin: 660 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 660 is unprofitable, but has reduced losses over the past 5 years at a rate of 24.3% per year.

Accelerating Growth: Unable to compare 660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 660 is unprofitable, making it difficult to compare its past year earnings growth to the Food industry (14.4%).


Return on Equity

High ROE: 660's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Wai Chun Bio-Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 660 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 660 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 660 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 660's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 660 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 660 has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.6% each year.


Dividend

What is Wai Chun Bio-Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 660's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 660's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 660's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 660's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 660's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average board tenure


CEO

Ching Kui Lam (62 yo)

9yrs

Tenure

HK$2,500,000

Compensation

Mr. Ching Kui Lam has been the Chief Executive Officer of Wai Chun Bio-Technology Limited (formerly known as Wai Chun Mining Industry Group Company Limited) and Wai Chun Group Holdings Limited since Januar...


CEO Compensation Analysis

Compensation vs Market: Ching Kui's total compensation ($USD320.85K) is above average for companies of similar size in the Hong Kong market ($USD233.34K).

Compensation vs Earnings: Ching Kui's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: 660's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Wai Chun Bio-Technology Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Wai Chun Bio-Technology Limited
  • Ticker: 660
  • Exchange: SEHK
  • Founded: NaN
  • Industry: Packaged Foods and Meats
  • Sector: Food, Beverage & Tobacco
  • Implied Market Cap: HK$90.761m
  • Shares outstanding: 1.68b
  • Website: https://www.0660.hk

Number of Employees


Location

  • Wai Chun Bio-Technology Limited
  • Admiralty Centre 2
  • 13th Floor
  • Admiralty
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 15:42
End of Day Share Price2022/01/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.